Huntington’s disease (HD) has been linked to reduced synthesis of cholesterol in the brain. Its exogenous delivery to the brain has been shown to be beneficial in the rapidly progressing R6/2 mouse model. Here we used an advanced formulation of brain-permeable nanoparticles (NPs) loaded with cholesterol and called hybrid-g7-NPs-chol, to explore the long-term therapeutical potential of cholesterol administration to the brain of the slow-progressing zQ175DN knock-in HD mouse model. We show that one cycle treatment with hybrid-g7-NPs-chol, administered in the pre-symptomatic or symptomatic phases, is sufficient to completely normalize cognitive defects up to 5 months, as well as to improve other behavioral and neuropathological parameters. Instead, two cycles of hybrid-g7-NPs-chol are needed to achieve long-lasting therapeutic benefits for 12 months without severe inflammatory side-effects. Sustained cholesterol delivery to the brain of zQ175DN mice also reduces mutant Huntingtin aggregates both in striatum and cortex and completely normalizes glutamatergic communication in the striatal medium spiny neurons compared to saline-treated HD mice. These results show that cholesterol delivery via brain-permeable NPs is a safe and versatile therapeutic option for lastingly reversing HD-related behavioral decline and neuropathological signs, highlighting the translational potential of cholesterol-based strategies in HD patients.

Cholesterol-laden brain-permeable nanoparticles support long-lasting cognitive recovery and motor amelioration in the slow-progressing zQ175DN mouse model of Huntington’s Disease / G. Birolini, M. Valenza, I. Ottonelli, F. Talpo, L. Minoli, A. Cappelleri, M. Bombaci, C. Caccia, V. Leoni, A. Passoni, M. Favagrossa, M.R. Nucera, L. Colombo, S. Paltrinieri, R. Bagnati, J. Thomas Duskey, R. Caraffi, M. Angela Vandelli, F. Taroni, M. Salmona, E. Scanziani, G.R. Biella, B. Ruozi, G.F. Tosi, E. Cattaneo. - (2022 Aug 26). [10.1101/2022.08.26.505426]

Cholesterol-laden brain-permeable nanoparticles support long-lasting cognitive recovery and motor amelioration in the slow-progressing zQ175DN mouse model of Huntington’s Disease

G. Birolini
Co-primo
;
M. Valenza
Co-primo
;
L. Minoli;A. Cappelleri;M.R. Nucera;S. Paltrinieri;E. Scanziani;G.R. Biella;G.F. Tosi;E. Cattaneo
Ultimo
2022

Abstract

Huntington’s disease (HD) has been linked to reduced synthesis of cholesterol in the brain. Its exogenous delivery to the brain has been shown to be beneficial in the rapidly progressing R6/2 mouse model. Here we used an advanced formulation of brain-permeable nanoparticles (NPs) loaded with cholesterol and called hybrid-g7-NPs-chol, to explore the long-term therapeutical potential of cholesterol administration to the brain of the slow-progressing zQ175DN knock-in HD mouse model. We show that one cycle treatment with hybrid-g7-NPs-chol, administered in the pre-symptomatic or symptomatic phases, is sufficient to completely normalize cognitive defects up to 5 months, as well as to improve other behavioral and neuropathological parameters. Instead, two cycles of hybrid-g7-NPs-chol are needed to achieve long-lasting therapeutic benefits for 12 months without severe inflammatory side-effects. Sustained cholesterol delivery to the brain of zQ175DN mice also reduces mutant Huntingtin aggregates both in striatum and cortex and completely normalizes glutamatergic communication in the striatal medium spiny neurons compared to saline-treated HD mice. These results show that cholesterol delivery via brain-permeable NPs is a safe and versatile therapeutic option for lastingly reversing HD-related behavioral decline and neuropathological signs, highlighting the translational potential of cholesterol-based strategies in HD patients.
Huntington; cholesterol; brain; nanoparticles
Settore BIO/14 - Farmacologia
https://www.biorxiv.org/content/10.1101/2022.08.26.505426v1
File in questo prodotto:
File Dimensione Formato  
2022.08.26.505426v1.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 4.09 MB
Formato Adobe PDF
4.09 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/946300
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact